Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
06 January 2014Website:
http://www.akaritx.comNext earnings report:
01 April 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 22 Nov 2024 00:52:43 GMTDividend
Analysts recommendations
Institutional Ownership
AKTX Latest News
- Secures $3.2m in PIPE Financing - - $50m Term Sheet Obtained for Available Financing under Equity Line of Credit -
BOSTON and LONDON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces shareholder approval in connection with the merger of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. At a General Meeting held in relation to the merger at 9:00 a.m. Eastern Time on Thursday, November 7, 2024 at the Company's offices in London, shareholders approved the Company's issuance of shares in connection with the proposed merger, with approximately 99% of shares present at the General Meeting, in person or by proxy, voted in support.
Samir R. Patel, M.D. Appointed Interim CEO; Interim CEO Employment Contract Demonstrates Alignment with Shareholders
Pre-IND meeting with FDA completed with positive feedback on clinical and nonclinical development plans for PAS-nomacopan in treatment of geographic atrophy Pre-IND meeting with FDA completed with positive feedback on clinical and nonclinical development plans for PAS-nomacopan in treatment of geographic atrophy
Agreed to merge with Peak Bio in a definitive agreement, anticipated to be finalized in the third quarter of 2024.
Akari Therapeutics, Plc will be presenting new pre-clinical data on investigational long-acting PAS-nomacopan, including its effect on electroretinography (ERG) testing in a blue light model, at the upcoming ARVO 2024 Annual Meeting in Seattle. Chief Scientific Officer Miles Nunn will provide an overview of the data in a poster presentation on Sunday, May 5 from 1:00 to 2:45 pm PT.
NEW YORK and BOSTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that President and CEO Rachelle Jacques will present a company overview for in-person and virtual attendees at Biotech Showcase taking place in San Francisco, CA January 8-10, 2024, adjacent to the J.P. Morgan Healthcare Conference 2024. Akari management will attend one-on-one meetings during the conferences.
BOSTON and LONDON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company will participate in the Emerging Growth Conference being held October 4 and 5, 2023. President and CEO Rachelle Jacques will present an overview of the company and its lead asset nomacopan, a bispecific inhibitor of complement C5 and leukotriene B4 (LTB4), on October 4, 2023 from 11:25 am to 11:55 am ET.
Penny stocks hold a distinctive charm for many investors. Amidst fluctuating market trends and the occasional downturn, there's often a group of these low-cost stocks surging in value.
There's something special about penny stocks. Even when the stock market is down, like it is today, you're likely to find at least a handful exploding higher.
What type of business is Akari Therapeutics?
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.
What sector is Akari Therapeutics in?
Akari Therapeutics is in the Healthcare sector
What industry is Akari Therapeutics in?
Akari Therapeutics is in the Biotechnology industry
What country is Akari Therapeutics from?
Akari Therapeutics is headquartered in United States
When did Akari Therapeutics go public?
Akari Therapeutics initial public offering (IPO) was on 06 January 2014
What is Akari Therapeutics website?
https://www.akaritx.com
Is Akari Therapeutics in the S&P 500?
No, Akari Therapeutics is not included in the S&P 500 index
Is Akari Therapeutics in the NASDAQ 100?
No, Akari Therapeutics is not included in the NASDAQ 100 index
Is Akari Therapeutics in the Dow Jones?
No, Akari Therapeutics is not included in the Dow Jones index
When was Akari Therapeutics the previous earnings report?
No data
When does Akari Therapeutics earnings report?
The next expected earnings date for Akari Therapeutics is 01 April 2025